<DOC>
	<DOCNO>NCT01968109</DOCNO>
	<brief_summary>To assess safety tolerability , characterize dose-limiting toxicity , identify maximum tolerate dose BMS-986016 alone combination Nivolumab subject select advanced ( metastatic and/or unresectable ) solid tumor provide preliminary information clinical benefit combination .</brief_summary>
	<brief_title>Safety Study Anti-LAG-3 With Without Anti-PD-1 Treatment Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . For Dose escalation : subject cervical , ovarian , bladder CRC , head neck , gastric hepatocellular cancer naive immunooncology agent ; 1st line melanoma 1st line/2nd line NSCLC ; Renal Cell Carcinoma naive IO ; NSCLC progress therapy antiPD1/antiPDL1 melanoma subject progress whileon treatment antiPD1 antiPDL1 without antiCTLA4 . For Dose Expansion : escalation except cervical , ovarian bladder CRC Progressed , intolerant , least one standard treatment regimen , except subject 1st line cohort . ECOG performance status 0 1 At least 1 lesion measurable disease baseline Availability exist tumor biopsy sample ( consent allow pretreatment tumor biopsy ) Primary central nervous system ( CNS ) tumor solid tumor CNS metastases site active disease Autoimmune disease Encephalitis , meningitis , uncontrolled seizure year prior inform consent Uncontrolled CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>